Codiak BioSciences Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
106
- Latest Deal Type
-
Bankr. Admin/Reorg
- Investors
-
5
Codiak BioSciences General Information
Description
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical needs. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Contact Information
Website
www.codiakbio.comCorporate Office
- 35 CambridgePark Drive
- Suite 500
- Cambridge, MA 02140
- United States
Corporate Office
- 35 CambridgePark Drive
- Suite 500
- Cambridge, MA 02140
- United States
Codiak BioSciences Timeline
Codiak BioSciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Bankruptcy: Admin/Reorg | 27-Mar-2023 | Completed | Bankruptcy: Admin/Reorg | |||
| 9. PIPE | 05-Jul-2022 | Completed | Generating Revenue | |||
| 8. Grant | 31-Dec-2021 | Completed | Generating Revenue | |||
| 7. 2PO | 12-Feb-2021 | Completed | Generating Revenue | |||
| 6. IPO | 14-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 5. Debt - General | 01-Oct-2019 | Completed | Pre-Clinical Trials | |||
| 4. IPO | 01-Jul-2019 | Cancelled | Pre-Clinical Trials | |||
| 3. Later Stage VC (Series C) | 29-Nov-2017 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series B) | 26-Jan-2016 | $61M | $92M | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 25-Nov-2015 | $31M | $31M | Completed | Product Development |
Codiak BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 33,200,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 29.48% |
Codiak BioSciences Comparisons
Industry
Financing
Details
Codiak BioSciences Competitors (35)
One of Codiak BioSciences’s 35 competitors is Artizan Biosciences, a Venture Capital-Backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Artizan Biosciences | Venture Capital-Backed | New Haven, CT | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Kimera Labs | Corporation | Miramar, FL | ||||
| Angle (United Kingdom) | Corporation | Guildford, United Kingdom | ||||
| AnTolRx | Venture Capital-Backed | Cambridge, MA |
Codiak BioSciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Codiak BioSciences Patents
Codiak BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2907967-T3 | Modified extracellular vesicles and their uses | Active | 16-Nov-2018 | ||
| JP-2023171899-A | Extracellular vesicles comprising sting agonist | Pending | 23-Mar-2018 | ||
| JP-2023133470-A | Exosomes for immuno-oncology and anti-inflammatory therapy | Pending | 28-Dec-2017 | ||
| JP-2024015074-A | Compositions of engineered exosomes and methods of loading luminal exosome payloads | Pending | 17-Nov-2017 | ||
| ES-2936149-T3 | Production of extracellular vesicles in single cell suspension using chemically defined cell culture media | Active | 21-Sep-2017 | C12P1/00 |
Codiak BioSciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Codiak BioSciences Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Coalition for Epidemic Preparedness Innovations | Impact Investing | Minority | ||
| United States Department of Defense | Government | |||
| ARCH Venture Partners | Venture Capital | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Flagship Pioneering | Venture Capital | Minority |
Codiak BioSciences ESG
Risk Overview
Risk Rating
Updated July, 09, 2022
34.78 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Pharmaceuticals
Subindustry
of 455
Rank
Percentile
Codiak BioSciences FAQs
-
When was Codiak BioSciences founded?
Codiak BioSciences was founded in 2015.
-
Where is Codiak BioSciences headquartered?
Codiak BioSciences is headquartered in Cambridge, MA.
-
What is the size of Codiak BioSciences?
Codiak BioSciences has 106 total employees.
-
What industry is Codiak BioSciences in?
Codiak BioSciences’s primary industry is Drug Discovery.
-
Is Codiak BioSciences a private or public company?
Codiak BioSciences is a Private company.
-
What is Codiak BioSciences’s current revenue?
The current revenue for Codiak BioSciences is .
-
How much funding has Codiak BioSciences raised over time?
Codiak BioSciences has raised $345M.
-
Who are Codiak BioSciences’s investors?
Coalition for Epidemic Preparedness Innovations, United States Department of Defense, ARCH Venture Partners, Fidelity Management & Research Company, and Flagship Pioneering have invested in Codiak BioSciences.
-
Who are Codiak BioSciences’s competitors?
Artizan Biosciences, Inovio Pharmaceuticals, Kimera Labs, Angle (United Kingdom), and AnTolRx are some of the 35 competitors of Codiak BioSciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
